Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis oleh Barbara Rewerska, MD, Lawrence D. Sher, MD, Sady Alpizar, MD, Sylvia Pauser, MD, Grazyna Pulka, MD, Neelufar Mozaffarian, MD, PhD, Yacine Salhi, PhD, Camille Martinet, MS, Wafaa Jabert, MS, Girish Gudi, PhD, Vinu CA, MPharm, MSc, Sunitha GN, PhD, Julie Macoin, MSc, Victor Anstett, MS, Riccardo Turrini, PhD, Marie-Agnès Doucey, PhD, Stanislas Blein, PhD, Cyril Konto, MD, Martina Machkova, MD